Sustainable release of carmustine from biodegradable poly[(d,l)-lactide-co- glycolide] nanofibrous membranes in the cerebral cavity

In vitro and in vivo studies

Yuan Yun Tseng, Jun Yi Liao, Wei An Chen, Yu Chun Kao, Shih Jung Liu

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans. The only interstitial chemotherapy pharmaceutical approved to date for GBM treatment is the Gliadel® wafer. Despite the safety and efficacy of this approach that have been demonstrated in patients undergoing resection of both newly diagnosed and recurrent malignant gliomas, the wafer provides an effective release of the anticancer 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for only 5 days. Methods: In this study, the authors developed biodegradable poly[(d,l)-lactide-co- glycolide] nanofibrous membranes via electrospinning that provided a sustained release of BCNU. An elution method and a HPLC assay were employed to characterize the in vitro and in vivo release behaviors of pharmaceuticals from the electrospun membranes. Results: The experimental results show that the biodegradable, nanofibrous membranes released high concentrations of BCNU for more than 6 weeks in the cerebral cavity of rats. Furthermore, the membranes can better conform to the geometry of the brain tissue and can cover more completely the tissue after the removal of tumors, achieving better drug transport without interfering with the normal function of the brain. Histological examination showed no obvious inflammation reactions of the brain tissues. Conclusion: Adopting the electrospinning technique will help in manufacturing biodegradable, nanofibrous membranes for the long-term deliveries of various anticancer drugs in the cerebral cavity, which will further enhance the therapeutic efficacy of GBM treatment.

Original languageEnglish
Pages (from-to)879-888
Number of pages10
JournalExpert Opinion on Drug Delivery
Volume10
Issue number7
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Carmustine
Glioblastoma
Membranes
Pharmaceutical Preparations
Brain
Encephalitis
Brain Neoplasms
Glioma
Therapeutics
High Pressure Liquid Chromatography
In Vitro Techniques
dilactide
Safety
Drug Therapy
Neoplasms

Keywords

  • BCNU
  • Chemotherapy
  • Drug-eluting membranes
  • Electrospinning
  • Glioblastoma multiforme
  • Nanofiber
  • Release characteristics

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Sustainable release of carmustine from biodegradable poly[(d,l)-lactide-co- glycolide] nanofibrous membranes in the cerebral cavity : In vitro and in vivo studies. / Tseng, Yuan Yun; Liao, Jun Yi; Chen, Wei An; Kao, Yu Chun; Liu, Shih Jung.

In: Expert Opinion on Drug Delivery, Vol. 10, No. 7, 07.2013, p. 879-888.

Research output: Contribution to journalArticle

@article{d11656896fba4663a96c6cd1324cd1bc,
title = "Sustainable release of carmustine from biodegradable poly[(d,l)-lactide-co- glycolide] nanofibrous membranes in the cerebral cavity: In vitro and in vivo studies",
abstract = "Objective: Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans. The only interstitial chemotherapy pharmaceutical approved to date for GBM treatment is the Gliadel{\circledR} wafer. Despite the safety and efficacy of this approach that have been demonstrated in patients undergoing resection of both newly diagnosed and recurrent malignant gliomas, the wafer provides an effective release of the anticancer 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for only 5 days. Methods: In this study, the authors developed biodegradable poly[(d,l)-lactide-co- glycolide] nanofibrous membranes via electrospinning that provided a sustained release of BCNU. An elution method and a HPLC assay were employed to characterize the in vitro and in vivo release behaviors of pharmaceuticals from the electrospun membranes. Results: The experimental results show that the biodegradable, nanofibrous membranes released high concentrations of BCNU for more than 6 weeks in the cerebral cavity of rats. Furthermore, the membranes can better conform to the geometry of the brain tissue and can cover more completely the tissue after the removal of tumors, achieving better drug transport without interfering with the normal function of the brain. Histological examination showed no obvious inflammation reactions of the brain tissues. Conclusion: Adopting the electrospinning technique will help in manufacturing biodegradable, nanofibrous membranes for the long-term deliveries of various anticancer drugs in the cerebral cavity, which will further enhance the therapeutic efficacy of GBM treatment.",
keywords = "BCNU, Chemotherapy, Drug-eluting membranes, Electrospinning, Glioblastoma multiforme, Nanofiber, Release characteristics",
author = "Tseng, {Yuan Yun} and Liao, {Jun Yi} and Chen, {Wei An} and Kao, {Yu Chun} and Liu, {Shih Jung}",
year = "2013",
month = "7",
doi = "10.1517/17425247.2013.758102",
language = "English",
volume = "10",
pages = "879--888",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Sustainable release of carmustine from biodegradable poly[(d,l)-lactide-co- glycolide] nanofibrous membranes in the cerebral cavity

T2 - In vitro and in vivo studies

AU - Tseng, Yuan Yun

AU - Liao, Jun Yi

AU - Chen, Wei An

AU - Kao, Yu Chun

AU - Liu, Shih Jung

PY - 2013/7

Y1 - 2013/7

N2 - Objective: Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans. The only interstitial chemotherapy pharmaceutical approved to date for GBM treatment is the Gliadel® wafer. Despite the safety and efficacy of this approach that have been demonstrated in patients undergoing resection of both newly diagnosed and recurrent malignant gliomas, the wafer provides an effective release of the anticancer 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for only 5 days. Methods: In this study, the authors developed biodegradable poly[(d,l)-lactide-co- glycolide] nanofibrous membranes via electrospinning that provided a sustained release of BCNU. An elution method and a HPLC assay were employed to characterize the in vitro and in vivo release behaviors of pharmaceuticals from the electrospun membranes. Results: The experimental results show that the biodegradable, nanofibrous membranes released high concentrations of BCNU for more than 6 weeks in the cerebral cavity of rats. Furthermore, the membranes can better conform to the geometry of the brain tissue and can cover more completely the tissue after the removal of tumors, achieving better drug transport without interfering with the normal function of the brain. Histological examination showed no obvious inflammation reactions of the brain tissues. Conclusion: Adopting the electrospinning technique will help in manufacturing biodegradable, nanofibrous membranes for the long-term deliveries of various anticancer drugs in the cerebral cavity, which will further enhance the therapeutic efficacy of GBM treatment.

AB - Objective: Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans. The only interstitial chemotherapy pharmaceutical approved to date for GBM treatment is the Gliadel® wafer. Despite the safety and efficacy of this approach that have been demonstrated in patients undergoing resection of both newly diagnosed and recurrent malignant gliomas, the wafer provides an effective release of the anticancer 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for only 5 days. Methods: In this study, the authors developed biodegradable poly[(d,l)-lactide-co- glycolide] nanofibrous membranes via electrospinning that provided a sustained release of BCNU. An elution method and a HPLC assay were employed to characterize the in vitro and in vivo release behaviors of pharmaceuticals from the electrospun membranes. Results: The experimental results show that the biodegradable, nanofibrous membranes released high concentrations of BCNU for more than 6 weeks in the cerebral cavity of rats. Furthermore, the membranes can better conform to the geometry of the brain tissue and can cover more completely the tissue after the removal of tumors, achieving better drug transport without interfering with the normal function of the brain. Histological examination showed no obvious inflammation reactions of the brain tissues. Conclusion: Adopting the electrospinning technique will help in manufacturing biodegradable, nanofibrous membranes for the long-term deliveries of various anticancer drugs in the cerebral cavity, which will further enhance the therapeutic efficacy of GBM treatment.

KW - BCNU

KW - Chemotherapy

KW - Drug-eluting membranes

KW - Electrospinning

KW - Glioblastoma multiforme

KW - Nanofiber

KW - Release characteristics

UR - http://www.scopus.com/inward/record.url?scp=84879370914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879370914&partnerID=8YFLogxK

U2 - 10.1517/17425247.2013.758102

DO - 10.1517/17425247.2013.758102

M3 - Article

VL - 10

SP - 879

EP - 888

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 7

ER -